Stryker Corp. (NYSE:SYK) on Thursday posted weaker-than-expected third-quarter results.

Revenue for the quarter came in at $6.52 billion, missing the analyst estimate of $6.61 billion by 1.36%. Still, net sales rose 7.7% year over year. Adjusted earnings per share were $3.52, missing the $3.55 expected by 0.85%.

The company also updated its 2026 guidance. It now expects organic net sales growth of 6.5% to 7.0% and adjusted EPS of $14.80 to $14.90.

“We delivered 7.7% organic sales growth and double-digit adjusted earnings growth in the quarter,” said Kevin A. Lobo, Chair and CEO. “While, in absolute terms, this reflected good overall performance, it did fall short of our expectations. The underlying fundamentals of the business remain strong, and we expect a solid performance in Q4 and good momentum heading into 2027.”

Stryker shares dipped 10.4% to $278.91 in pre-market trading

These analysts made changes to their price targets on Stryker following earnings announcement.

• BTIG analyst Ryan Zimmerman maintained the stock with a Buy and lowered the price target from $316 to $304.
• Needham analyst Mike Matson maintained the stock with a Buy and lowered the price target from $418 to $359.

Considering buying SYK stock? Here’s what analysts think:

Photo via Shutterstock

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.